Complications of Surgery for Myopic Foveoschisis
Myopic traction maculopathy poses a risk.
ALAN HROMAS, MD • JOHNNY TANG, MD
Myopic foveoschisis (MFS) represents a potential cause of significant vision loss in highly myopic patients with a posterior staphyloma.1-5 Schisis alone may or may not significantly impair visual acuity (Figure 1); however, MFS may be associated with foveal retinal detachment, macular hole, or a combination of the two,5 as part of a spectrum of disorders that has been called myopic traction maculopathy (MTM).6
Figure 1. Color fundus photos of the right (A) and left (B) eyes and the corresponding OCT images (C and D) of a 43-year-old female patient with myopic foveoschisis. Best-corrected visual acuity was 20/40 bilaterally.
COURESTY OF HASSAN RAHMAN, MD
MTM has been postulated to be secondary to numerous factors, including vitreomacular traction, tangential traction from epiretinal membrane or from vitreous cortex remnants following posterior vitreous detachment, or relative stiffness of the internal limiting membrane overlying the staphyloma.7-9
SURGERY FOR MYOPIC TRACTION MACULOPATHY
Eyes initially presenting with MFS may progress to requiring surgery in 28.5% to 50% of cases,2 with the most common indications for surgery being progressive macular thickening with resultant visual decline or visual decline associated with the aforementioned macular hole or foveal retinal detachment.2,3,10,11
Surgical treatment has been found to be beneficial in many cases of MFS, particularly those cases accompanied by foveal retinal detachment,12 although the indications for surgical intervention and the specific procedure of choice are controversial.
Alan Hromas, MD, is a second-year vitreoretinal surgery fellow at Retina and Vitreous of Texas in Houston. Johnny Tang, MD, practices with Eye Health Vision Centers in New England. Neither author has financial interests to disclose related to topics mentioned in this article. Dr. Hromas can be reached via e-mail at firstname.lastname@example.org.
In general, surgical strategies involve decreasing or countering the tractional factors previously noted. The presence of the posterior staphyloma and the frequent coprevalance of myopic degeneration, retinal pigment epithelial atrophy, and choroidal neovascularization may limit the expected postoperative best corrected visual acuity13 and the chance of anatomical surgical success.14
The proposed surgical treatments for diseases of the MTM spectrum may employ an external, buckling approach or a transvitreal approach. Macular scleral buckling has been largely supplanted by the transvitreal approach of pars plana vitrectomy, although both procedures are still used.5,12,15-20
Potential complications of surgical repair include those inherent to scleral buckling or vitrectomy in general, in addition to those complications that are significantly more common in patients with MTM. Herein, we discuss these potential shared and unique complications.
Macular Scleral Buckling
Some authors still consider macular scleral buckling to be the initial procedure of choice in these cases; it can also be used as a secondary procedure following failed vitrectomy.6 The procedure is regarded as technically challenging by some, with a great deal of reported variation in surgical technique.18
While a detailed discussion of any specific surgical technique is beyond the scope of this article, the macular buckling procedure generally involves creating an indentation within the posterior staphyloma, using a specially designed plomb and thus “correcting” the anatomical abnormality, which is chiefly responsible for the pathologic tractional findings.
While surgeons and centers experienced in the macular buckling procedure may find a great deal of success, their results may not be reproducible in less-experienced hands, especially in an era when even primary scleral buckling for retinal detachment repair is becoming less frequent in favor of primary vitrectomy.
The potential complications of macular scleral buckling include postoperative pain, metamorphopsia, extrusion of the buckling element, scleral laceration during suturing, injury to the optic nerve head or vortex vein, postoperative intraocular pressure elevation, cystoid macular edema, macular scarring, irregular astigmatism, and limitation of ocular motility.15,20 Extrusion, intractable pain, metamorphopsia, or diplopia may require removal of the explant.6
Pars Plana Vitrectomy
Currently, the transvitreal approach of PPV is more commonly employed as a treatment for the MTM spectrum as compared to buckling. As in macular scleral buckling, there is a great deal of variation in reported technique and surgical procedure. Generally, a core vitrectomy is performed, and a posterior vitreous detachment is induced when not already present.
Various authors have advocated peeling of any residual preretinal vitreous cortex or ERM, followed by peeling of the ILM.12,14,19,21 Surgeons may then choose to use no internal tamponade or tamponade with air,22 gas, or silicone oil.23
There are generally accepted complications inherent to PPV regardless of the surgical indication: PPV for macular pathology, in general, entails a well-documented risk of iatrogenic retinal breaks,24-27 retinal detachment, and worsening of pre-existing nuclear sclerotic cataract.28
Anteroposterior traction by an adherent posterior hyaloid is believed to be a significant causative factor in MTM pathogenesis, and the induction of a PVD is an important step in all MTM vitrectomy cases. It is therefore notable that surgical induction of a PVD is associated with an even further increase in the risk of retinal tears,26,27 as well as a risk of iatrogenic postoperative full-thickness macular hole.
REMOVAL OF POSTERIOR VITREOUS CORTEX AND EPIRETINAL MEMBRANE
In addition to the induction of a PVD, treatment for all forms of MTM generally involves removal of premacular structures, including any residual posterior vitreous cortex (PVC) and ERM. Although histologically distinct, both structures are believed to exert oblique or tangential traction on the perifoveal macula, possibly decreasing retinal compliance over the posterior staphyloma and favoring the development of foveal retinal detachment, macular hole, or both.
Removal involves forceps peeling, often with use of visualization aids; triamcinolone acetonide is commonly used to aid in the visualization of residual PVC, while trypan blue is often used to delineate ERM.29
The most notable potential complication of the removal of premacular structures is probably inadvertent mechanical damage to the retina during forceps peeling, a risk that is present in any vitrectomy surgery involving forceps peeling of preretinal structures but that is perhaps more likely in highly myopic eyes. Additionally, the visualization aids used to accomplish removal each carry their own risks.
Triamcinolone particles adhere to residual vitreous or PVC and thus enhance the visualization of these structures. Use of triamcinolone appears to reduce the risk of intraoperative retinal breaks and is generally regarded as safe, although it can be associated with a transient IOP elevation following use.30
It is notable that, while perhaps commonly used intraocularly, the commercial triamcinolone preparation Kenalog-40 (Bristol-Myers Squibb, New York, NY) contains the possibly toxic preservative 0.99% benzyl alcohol, and the product is not approved for intraocular use.31 A preservative-free triamcinolone preparation is commercially available (Triesence, Alcon, Fort Worth, TX).
Trypan blue is also generally regarded as having a low risk of toxicity to the neurosensory retina, although accidental subretinal injection has been reported.32 Subretinal trypan blue may result in RPE atrophy, secondary to either a toxic effect of the dye itself or the force with which it was injected.
Ensuring that the trypan blue injection cannula is not aimed directly at the macula reduces the chance of causing subretinal injection within the macula, resulting in parafoveal patches of macular RPE atrophy.
ILM peeling has been repeatedly suggested to increase the odds of successful surgery in all stages of MTM.21,33-38 In addition to ensuring that all residual hyaloid and ERM are removed, ILM removal is believed to increase retinal compliance and presumably to allow the retina to better conform to the posterior staphyloma.
Peeling of the ILM in highly myopic eyes may be more technically challenging than in otherwise normal eyes, and it has been suggested that an adequate peel area in MTM cases may be necessarily more extensive: myopic patients may benefit from peeling the ILM over the entire retina overlying the staphyloma, as opposed to peeling the immediate perifoveal area only, as is often performed in surgery for idiopathic macular hole. Peeling a larger area may, in turn, increase the risk of mechanical damage to the retina via repeated grasping of the ILM.28
Various vital stains have been used to enhance visualization of the ILM, with indocyanine green and brilliant blue G most commonly used.14,39,40 Both dyes have been shown to be effective, and they appear to increase the chance of successful ILM removal, although the use of either is not without risk.
ICG has a well-documented risk of toxicity to the RPE, and it has been described as producing irreversible RPE atrophy with corresponding vision loss; this risk may be greater in highly myopic patients with chorioretinal atrophy or pre-existing attenuation of the RPE.29,41-43 In comparison, there appear to be fewer toxicity concerns with brilliant blue G, although numerous case reports have been published. Accidental subretinal injection of both agents has been reported.29,44
Various authors have utilized internal tamponade in surgery for the MTM spectrum. Air, sulfur hexafluoride (SF6), perfluoropropane (C3F8), and silicone oil have all been used with some degree of success in patients with MFS, foveal detachment, and macular hole.2,8,18,22
While it is generally agreed that internal tamponade increases the odds of successful repair in macular hole cases, multiple authors have suggested that tamponade is unnecessary when no full-thickness hole or retinal defect is present.19,45
The primary risk involved with intraocular tamponade is postoperative IOP elevation, which may be related to an intentionally or unintentionally expansile concentration of gas or an overfill of gas or silicone oil. In most cases, the IOP elevation can be managed medically.46
PRIMARY AND IATROGENIC MACULAR HOLE
Macular hole may occur in highly myopic eyes with MTM without iatrogenic provocation or as a complication of surgery for MFS. Postoperative macular hole is a recognized complication of PPV for MFS, with an incidence ranging from 19% to 27%,17,47 which is significantly higher than an estimated rate of 1% following vitrectomy for retinal detachment.48
The incidence of new postoperative macular hole appears to be higher when there is a concurrent foveal retinal detachment,47 if there is a pre-existing outer retinal defect,17 or if the ILM is peeled using a standard technique. Shimada et al described a fovea-sparing method of ILM peeling, which reportedly decreased the chance of postoperative macular hole.49
Macular hole in highly myopic patients is more difficult to manage than idiopathic macular hole in otherwise normal eyes.20 Macular hole furthermore may produce a concurrent retinal detachment in highly myopic patients with a posterior staphyloma (Figure 2).
Figure 2. OCT of a 56-year-old female patient with myopic foveoschisis, macular hole, and foveal detachment. Best-corrected visual acuity was 20/100.
COURTESY OF EMMANUEL CHANG, MD, PhD
Repair requires reoperation with either macular scleral buckling or repeat PPV, wider peeling of residual ILM,50 gas tamponade, and possibly postoperative face-down positioning. Even with a surgical repair free of complications, the rate of successful macular hole closure and repair of the associated retinal detachment via vitrectomy has remained limited at 46% to 75%.36
The surgical management of MTM remains controversial despite advances in vitreoretinal surgery, with many advocates for both buckling and vitrectomy approaches. Given the lack of consensus regarding the procedure of choice for this disease spectrum, perhaps the most important step in management is to provide patients with adequate preoperative informed consent.
While many myopic patients exhibiting traction-related pathology may benefit from operative intervention, the risk of complications in such cases exceeds those standard for vitreoretinal surgery. Furthermore, the likelihood of surgical success, particularly in the case of myopic macular holes or myopic macular hole-related retinal detachments, is expected to be significantly lower than that expected for uncomplicated idiopathic macular hole or rhegmatogenous retinal detachment.
The relatively high incidence of new, iatrogenic postoperative macular holes in this patient group is especially concerning, given that repair may require a second or third surgical procedure and additional uncomfortable face-down positioning.
Explaining this complication only after the fact may serve to undermine patient confidence in the surgical team. Ensuring that patients understand the risk of this frustrating situation, as well as the risk of other possible complications, beforehand will help to maintain patient trust should additional intervention eventually become necessary. RP
1. Champion M, Tang J. New perspectives on myopic foveoschisis. Retin Physician. 2013;10:30-39.
2. Rey A, Jürgens I, Maseras X, Carbajal M. Natural course and surgical management of high myopic foveoschisis. Ophthalmologica. 2014;231:45-50.
3. Shimada N, Ohno-Matsui K, Baba T, Futagami S, Tokoro T, Mochizuki M. Natural course of macular retinoschisis in highly myopic eyes without macular hole or retinal detachment. Am J Ophthalmol. 2006;142:497-500.
4. Benhamou N, Massin P, Haouchine B, Erginay A, Gaudric A. Macular retinoschisis in highly myopic eyes. Am J Ophthalmol. 2002;133:794-800.
5. Gohil R, Sivaprasad S, Han LT, Mathew R, Kiousis G, Yang Y. Myopic foveoschisis: a clinical review. Eye (Lond). 2015;29:593-601.
6. Parolini B, Frisina R, Pinackatt S, et al. Indications and results of a new L-shaped macular buckle to support a posterior staphyloma in high myopia. Retina. 2015 Jun 15. [Epub ahead of print]
7. Gómez-Resa M, Burés-Jelstrup A, Mateo C. Myopic traction maculopathy. Dev Ophthalmol. 2014;54:204-212.
8. Johnson MW. Myopic traction maculopathy: pathogenic mechanisms and surgical treatment. Retina. 2012;32(Suppl 2):S205-S210.
9. Tang J, Rivers MB, Moshfeghi AA, Flynn HW, Chan C-C. Pathology of macular foveoschisis associated with degenerative myopia. J Ophthalmol. 2010;2010.
10. Wu P-C, Chen Y-J, Chen Y-H, et al. Factors associated with foveoschisis and foveal detachment without macular hole in high myopia. Eye (Lond). 2009;23:356-361.
11. Takano M, Kishi S. Foveal retinoschisis and retinal detachment in severely myopic eyes with posterior staphyloma. Am J Ophthalmol. 1999;128:472-476.
12. Mii M, Matsuoka M, Matsuyama K, Otsu Y, Nishimura T. Favorable anatomic and visual outcomes with 25-gauge vitrectomy for myopic foveoschisis. Clin Ophthalmol. 2014;8:1837-1844.
13. Shih Y-F, Ho T-C, Hsiao CK, Lin LL-K. Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study. Br J Ophthalmol. 2006;90:546-550.
14. Wei Y, Wang N, Zu Z, et al. Efficacy of vitrectomy with triamcinolone assistance versus internal limiting membrane peeling for highly myopic macular hole retinal detachment. Retina. 2013;33:1151-1157.
15. Ando F, Ohba N, Touura K, Hirose H. Anatomical and visual outcomes after episcleral macular buckling compared with those after pars plana vitrectomy for retinal detachment caused by macular hole in highly myopic eyes. Retina. 2007;27:37-44.
16. Chang JS, Flynn HW, Engelbert M, Shane AR, Smiddy WE, Chang S. Pars plana vitrectomy in patients with myopic macular retinoschisis. Br J Ophthalmol. 2014;98:534-537.
17. Gao X, Ikuno Y, Fujimoto S, Nishida K. Risk factors for development of full-thickness macular holes after pars plana vitrectomy for myopic foveoschisis. Am J Ophthalmol. 2013;155:1021-1027.
18. Ortisi E, Avitabile T, Bonfiglio V. Surgical management of retinal detachment because of macular hole in highly myopic eyes. Retina. 2012;32:1704-1718.
19. Uchida A, Shinoda H, Koto T, et al. Vitrectomy for myopic foveoschisis with internal limiting membrane peeling and no gas tamponade. Retina. 2014;34:455-460.
20. Burés-Jelstrup A, Alkabes M, Gómez-Resa M, Rios J, Corcóstegui B, Mateo C. Visual and anatomical outcome after macular buckling for macular hole with associated foveoschisis in highly myopic eyes. Br J Ophthalmol. 2014;98:104-109.
21. Kadonosono K, Yazama F, Itoh N, et al. Treatment of retinal detachment resulting from myopic macular hole with internal limiting membrane removal. Am J Ophthalmol. 2001;131:203-207.
22. Wolfensberger TJ, Gonvers M, Bovey E. Very long-term follow-up of retinal detachment due to macular hole treated with vitrectomy and air injection. Retina. 2001;21:678-681.
23. Meng L, Wei W, Li Y, Han X, Shi X, Yang M. Treatment of retinal detachment secondary to macular hole in highly myopic eyes. Retina. 2014;34:470-476.
24. Nakano T, Uemura A, Sakamoto T. Incidence of iatrogenic peripheral retinal breaks in 23-gauge vitrectomy for macular diseases. Retina. 2011;31:1997-2001.
25. Tan HS, Mura M, de Smet MD. Iatrogenic retinal breaks in 25-gauge macular surgery. Am J Ophthalmol. 2009;148:427-430.
26. Chung SE, Kim K-H, Kang SW. Retinal breaks associated with the induction of posterior vitreous detachment. Am J Ophthalmol. 2009;147:1012-1016.
27. Yagi F, Takagi S, Tomita G. Incidence and causes of iatrogenic retinal breaks in idiopathic macular hole and epiretinal membrane. Semin Ophthalmol. 2014;29:66-69.
28. Steel DHW, Lotery AJ. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. Eye (Lond). 2013;27(Suppl 1):S1-S21.
29. Hernández F, Alpizar-Alvarez N, Wu L. Chromovitrectomy: an update. J Ophthalmic Vis Res. 2014;9:251-259.
30. Sakamoto T, Ishibashi T. Visualizing vitreous in vitrectomy by triamcinolone. Graefes Arch Clin Exp Ophthalmol. 2009;247:1153-1163.
31. Tao Y, Jonas JB. Intravitreal triamcinolone. Ophthalmologica. 2011;225:1-20.
32. Ghosh S, Issa S, El Ghrably I, Stannard K. Subretinal migration of trypan blue during macular hole and epiretinal membrane peel: an observational case series. Is there a safer method? Eye (Lond). 2010;24:1724-1727.
33. Cho H, Choi A, Kang SW. Effect of internal limiting membrane removal in treatment of retinal detachment caused by myopic macular hole. Kor J Ophthalmol. 2004;18:141-147.
34. Germano RAS, Zacharias LC, Takahashi WY. Recurrent myopic foveoschisis: resolution after internal limiting membrane removal. Arq Bras Oftalmol. 2015;78:44-46.
35. Brazitikos PD, Androudi S, Dimitrakos SA, Stangos NT. Removal of the internal limiting membrane under perfluorocarbon liquid to treat macular-hole-associated retinal detachment. Am J Ophthalmol. 2003;135:894-896.
36. Su J, Liu X, Zheng L, Cui H. Vitrectomy with internal limiting membrane peeling vs no peeling for macular hole-induced retinal detachment (MHRD): a meta-analysis. BMC Ophthalmol. 2015;15:62.
37. Figueroa MS, Ruiz-Moreno JM, Gonzalez Del Valle F, et al. Long-term outcomes of 23-gauge pars plana vitrectomy with internal limiting membrane peeling and gas tamponade for myopic traction maculopathy. A prospective study. Retina. 2015 May 5. [Epub ahead of print]
38. Uemoto R, Yamamoto S, Tsukahara I, Takeuchi S. Efficacy of internal limiting membrane removal for retinal detachments resulting from a myopic macular hole. Retina. 2004;24:560-566.
39. Shukla D, Kalliath J, Neelakantan N, Naresh KB, Ramasamy K. A comparison of brilliant blue G, trypan blue, and indocyanine green dyes to assist internal limiting membrane peeling during macular hole surgery. Retina. 2011;31:2021-2025.
40. Baba T, Hagiwara A, Sato E, Arai M, Oshitari T, Yamamoto S. Comparison of vitrectomy with brilliant blue G or indocyanine green on retinal microstructure and function of eyes with macular hole. Ophthalmology. 2012;119:2609-2615.
41. Rodrigues EB, Meyer CH, Farah ME, Kroll P. Intravitreal staining of the internal limiting membrane using indocyanine green in the treatment of macular holes. Ophthalmologica. 2005;219:251-262.
42. Gandorfer A, Haritoglou C, Kampik A. Toxicity of indocyanine green in vitreoretinal surgery. Dev Ophthalmol. 2008;42:69-81.
43. Rodrigues EB, Meyer CH, Mennel S, Farah ME. Mechanisms of intravireal toxicity of indocyanine green dye. Retina. 2007;27:958-970.
44. Almeida FPP, De Lucca AC, Scott IU, Jorge R, Messias A. Accidental subretinal brilliant blue G migration during internal limiting membrane peeling surgery. JAMA Ophthalmol. 2015;133:85-88.
45. Kim KS, Lee SB, Lee WK. Vitrectomy and internal limiting membrane peeling with and without gas tamponade for myopic foveoschisis. Am J Ophthalmol. 2012;153:320-326.
46. Hasegawa Y, Okamoto F, Sugiura Y, Okamoto Y, Hiraoka T, Oshika T. Intraocular pressure elevation after vitrectomy for various vitreoretinal disorders. Eur J Ophthalmol. 2014;24:235-241.
47. Gaucher D, Haouchine B, Tadayoni R, et al. Long-term follow-up of high myopic foveoschisis: natural course and surgical outcome. Am J Ophthalmol. 2007;143:455-462.
48. Fabian ID, Moisseiev E, Moisseiev J, Moroz I, Barak A, Alhalel A. Macular hole after vitrectomy for primary rhegmatogenous retinal detachment. Retina. 2012;32:511-519.
49. Shimada N, Sugamoto Y, Ogawa M, Takase H, Ohno-Matsui K. Fovea-sparing internal limiting membrane peeling for myopic traction maculopathy. Am J Ophthalmol. 2012;154:693-701.
50. Che X, He F, Lu L, et al. Evaluation of secondary surgery to enlarge the peeling of the internal limiting membrane following the failed surgery of idiopathic macular holes. Exp Ther Med. 2014;7:742-746.